The Associated PressItalian biopharmaceutical company Gentium SpA said Wednesday results from a late-stage study of its drug Defibrotide failed to show a level of statistical significance required for proof of efficacy.
Gentium Encouraged By Late-stage Defibrotide Trial
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.